.Attributes Medication, Posted online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antibody-- drug conjugate (ADC) tisotumab vedotin caused improved progression-free as well as total survival, leading to FDA approval as well as a brand new procedure choice for individuals.